retatrutide type 1 diabetes The Effect of on Kidney Parameters in Participants With 2 Mellitus and/or Obesity retatrutide triple agonist glp-1 gip

Long-term cardiovascular outcomes data are not yet available, as dedicated trials have not been completed

Others follow the standard once-weekly protocol and lose 24% of their body weight in under a year

Maintenance dosing considerations Not everyone needs or tolerates the 12mg maximum dose

As with semaglutide, improvements in delivery of retatrutide and identification of new targets, such as FGF21, could offer even more elegant solutions

Chronic inflammation, obesity, and brain health Chronic inflammation, a hallmark of obesity, is associated with an increased risk of developing neurological conditions, including cognitive decline and neurodegeneration